Stay updated with breaking news from Important Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy – ...
TIVDAK sBLA accepted for priority review, FDA action date is May 9, 2024 Submission based on positive results from global phase 3 innovaTV 301 trial demonstrating overall survival benefit of...
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16% at CER
Estate Tag Sales, Live & Online Auctions, Licensed Auctioneer, Estate Buyouts 319-845-6014 Licensed * Bonded * Insured
- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023,...